Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization

Romero, Martin; Góngora, David-Steven; Caicedo, Martha-Lucia; Benchabane, Damia; Lopez, Juan-Guillermo

doi:10.1016/j.vhri.2021.06.001

Cited by 5 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were the incentives to investigate more in depth the rates of infection of pentavalent vaccines to be reconstituted versus the hexavalent vaccine that is ready to be used and estimate their cost difference. Studies on the economic value of the hexavalent vaccine suggested the following costs to be assessed: cost of the vaccine, cost of inpatient and/or outpatient visits, delivery cost, time cost, labor cost, cost for immunization errors and adverse events, and waste cost [ 18 , 19 , 20 , 21 ]. Our study adds the cost of infection contamination following immunization using the results of a model construct.…”

Section: Introductionmentioning

confidence: 99%

Estimating the Total Societal Cost of a Hexavalent Vaccine versus a Pentavalent Vaccine with Hepatitis B in South Korea

et al. 2023

View full text Add to dashboard Cite

In South Korea, the ready-to-use hexavalent vaccine (against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and hepatitis B) is not listed despite its facility of no need to reconstitute. It, therefore, has the potential to augment the efficiency of prevention against the six infectious diseases, and it may reduce vaccine-related errors of reconstitution when compared with the currently used vaccination scheme of the pentavalent vaccine with the additional shots against hepatitis B. Given the assumed clinical equivalence between the two vaccination schemes, a cost-minimization analysis has been performed from a societal perspective including all the medical and non-medical direct and indirect costs when vaccinating one birth cohort. The results indicate that the ready-to-use hexavalent vaccine induces a cost reduction of KRW 47,155 (USD36.22) per infant or 12,026 million Korean Won ($9,236,417) in total for the whole birth cohort with 260,500 children. Using the ready-to-use hexavalent vaccine causes a lower infection rate, has fewer vaccination sessions, and may save much time as compared with the current vaccination scheme in place. The ready-to-use hexavalent vaccine may, therefore, benefit the National Immunization Program by reducing the total societal costs of vaccination while improving convenience of infants, parents, and medical care professionals.

show abstract